EP300 inhibitors have emerged as promising novel antitumor agents for clinical translation.[22] Specifically, inobrodib (CCS1477), an EP300 bromodomain inhibitor, is under clinical evaluation for patients with advanced and drug‐resistant solid tumors or hematological malignancies. The gene discussed is EP300; the disease is hematologic disorder.